Evaluation of the Effect of Telmisartan (Micardis® 80 mg/ MicardisPlus® 80/12.5 mg) on Blood Pressure and Cardiovascular Risk Factor Index in High Risk Hypertensive Patients

Boehringer Ingelheim

Status: Completed

Conditions: Hypertension; Cardiovascular Diseases

Study type: Observational

Funder types: Industry

Identifiers

NCT00904371

502.585

Details and patient eligibility

About

The study is designed to evaluate the effect of treatment with Micardis/MicardisPlus on blood pressure and its ability to reduce different indicated cardiovascular risks. Further on, the study will evaluate the current antihypertensive treatment pattern in the daily practice among the patient population at increased cardiovascular risk.

Enrollment: 211 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• diagnosis of essential arterial hypertension (BP>140/90 mm HG or BP>130/80 mm Hg for diabetic patients)
• at least an additional cardiovascular risk factor

Exclusion criteria

• hypersensitivity to the active substance or to any of the excipients in any ACE inhibitor or angiotensin receptor blocker (ARB) available on the local market
• pregnancy and lactation
• diseases involving biliary obstruction
• severe liver impairment

Trial design

211 participants in 1 patient group

Patients with arterial hypertention